| Autor: |
Barrett-Connor E; Dr. Elizabeth Barrett-Connor is Distinguished Professor, Division of Epidemiology, Department of Family Medicine and Public Health at the University of California, San Diego, La Jolla, CA, Wingard D; Dr. Deborah Wingard is Professor, Division of Epidemiology, Department of Family Medicine and Public Health at the University of California, San Diego, La Jolla, CA, Wong N; Dr. Nathan Wong is Professor and Director of the Heart Disease Prevention Program, Division of Cardiology, University of California, Irvine, Irvine, CA, Goldberg R; Dr. Ron Goldberg is Professor of Medicine and Biochemistry and Molecular Biology, Division of Endocrinology, Diabetes and Metabolism, Diabetes Research Institute, University of Miami Miller School of Medicine, Miami, FL |
| Abstrakt: |
Heart disease remains a major cause of morbidity and mortality in type 2 diabetes and is estimated to account for 10%–11% of all vascular deaths. Surveys of the U.S. population have demonstrated an age-standardized differential for heart disease in adults with mostly type 2 diabetes that varies from 1.9 to 2.5. The age-standardized prevalence is about 50% higher in men than women overall and for most categories of heart disease, except congestive heart failure. Although rates of diabetes are higher in nonwhites than in non-Hispanic whites, it should be noted that non-Hispanic whites with diabetes generally report heart disease rates about 50% higher than Hispanic subjects with diabetes, with an intermediate prevalence in non-Hispanic blacks. Despite an approximate doubling in type 2 diabetes prevalence from the 1980s to the 2010s, the prevalence of heart disease in diabetes has remained stable. Classic heart disease risk factors, such as elevated low-density lipoprotein (LDL) cholesterol, blood pressure, reduced high-density lipoprotein (HDL) cholesterol, and smoking, have been clearly demonstrated to be important determinants of heart disease in diabetes. However, several studies, including a very large, multinational meta-analysis, indicate that the excess prevalence of heart disease in diabetes is not accounted for by measured classic cardiovascular disease (CVD) risk factors, including levels of triglyceride, HDL cholesterol, non-HDL cholesterol, C-reactive protein, fibrinogen, and renal function. In addition, novel biomarkers have not been found to add significance in prediction of heart disease. The association between fasting glucose and heart disease displays a J-shaped curve in several studies, indicating that the risk for heart disease in subjects with fasting plasma glucose 100–125 mg/dL is only modestly elevated compared to the twofold higher risk in those with values ≥126 mg/dL, the current cut point for diagnosis of type 2 diabetes. Glycosylated hemoglobin (A1c) has also been shown to have a graded association with heart disease. The association between insulin resistance and heart disease is inconsistent, at least in part because of methodologic differences among studies. Furthermore, these studies may be complicated by cross-reactivity with proinsulin, which is a marker for beta cell failure and may be more strongly associated with heart disease than insulin levels. Obesity is the most important risk factor for type 2 diabetes but has not been shown to have an independent association with heart disease. Although similar associations with heart disease have been found for body mass index and waist measurements in a large meta-analysis of general population cohort studies, these were lost after adjustment for other risk factors, possibly because obesity is in the causal pathway between these risk factors and heart disease development. Similarly, conflicting data have been reported as to whether the presence of the metabolic syndrome in subjects with diabetes is independently associated with heart disease. In contrast to body weight, physical inactivity in those with diabetes appears to have an independent association with heart disease. Clinical trials involving risk factor modification in diabetes have helped to clarify their roles in heart disease development, as well as the benefits and limitations of modern treatment modalities for diabetes and its complications, and have led to significant modification in treatment guidelines. Whether improvement of glycemic control reduces heart disease has long been a central question, since older trials had not demonstrated benefit. However, extended follow-up of earlier studies of improved glycemic control in both type 1 and type 2 diabetes have demonstrated a long-term so-called “legacy” benefit for heart disease, not immediately evident after completion of the active intervention phase. Intervention trials testing intensive versus standard glycemic control, however, have found no evidence of benefit of improved glycemic control on cardiovascular outcomes. In one of these trials, cardiovascular and all-cause mortality increased in the intensive control group, while a meta-analysis of 13 trials of intensive glycemic control found no significant impact on all-cause mortality. Severe hypoglycemia, longstanding diabetes, and preexisting heart disease appeared to contribute to the increased mortality and the lack of benefit for intensive glycemic control, and post hoc analyses suggested that this intervention may be most effective in more recently diagnosed subjects. With respect to lipid-lowering clinical trials, by contrast, studies have shown unequivocally that statin treatment, in both secondary as well as primary prevention trials, significantly reduces heart disease with a similar risk reduction to that seen in nondiabetic subjects. However, fenofibrate given as monotherapy or as add-on therapy to simvastatin does not confer heart disease benefit in diabetes, except possibly in the subgroup with high triglyceride and low HDL cholesterol levels. While older trials of blood pressure lowering demonstrated benefit, a more recent large trial of intensive blood pressure control did not find that achieving a lower goal leads to a reduction in cardiovascular events overall, although ischemic stroke incidence was decreased. Several trials were unable to demonstrate a significant benefit for low-dose aspirin as primary preventive therapy in diabetes. Finally, although there have been few studies of comprehensive risk factor management, one small, long-term trial was highly successful in reducing cardiovascular events by intensive glycemic blood pressure and LDL cholesterol control. In addition, a meta-analysis of physical activity trials in patients with diabetes showed a reduction in myocardial infarction and all-cause mortality. However, a large 10-year clinical trial focusing on weight reduction in people with diabetes through an intensive lifestyle change program showed no cardiovascular benefit despite improvement in risk factors. In conclusion, despite intensive management of risk factors, the high risk for heart disease among people with diabetes remains a major health concern. |
